HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on UroGen Pharma (NASDAQ:URGN) and maintained a price target of $60.
August 14, 2024 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on UroGen Pharma and maintained a price target of $60.
The reiteration of a Buy rating and a maintained price target of $60 by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100